MAIA BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.89 USD | -4.93% |
|
-8.25% | +147.01% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 38.42 | 19.82 | 59.48 | - |
| Enterprise Value (EV) 1 | 38.42 | 19.82 | 59.48 | 59.48 |
| P/E ratio | -2.01 x | -0.79 x | -1.82 x | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 1.68 x |
| EV / Revenue | - | - | - | 1.68 x |
| EV / EBITDA | -2.38 x | -0.98 x | -2.02 x | -1.68 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 10,946 | 16,944 | 20,581 | - |
| Reference price 2 | 3.510 | 1.170 | 2.890 | 2.890 |
| Announcement Date | 3/24/23 | 3/21/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 35.39 |
| EBITDA 1 | - | -16.18 | -20.18 | -29.48 | -35.39 |
| EBIT 1 | - | -16.18 | -20.18 | -33.48 | -34.54 |
| Operating Margin | - | - | - | - | -97.62% |
| Earnings before Tax (EBT) 1 | - | -15.77 | -19.77 | -33.49 | -34.55 |
| Net income 1 | -12.5 | -16.22 | -19.77 | -33.49 | -34.55 |
| Net margin | - | - | - | - | -97.64% |
| EPS 2 | -2.370 | -1.750 | -1.490 | -1.585 | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/11/22 | 3/24/23 | 3/21/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | -5.294 | -4.184 | -4.665 | -4.956 | -6.378 | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -5.117 | -4.117 | -4.524 | -4.876 | -6.257 | - | - | - | - |
| Net income | - | -5.568 | -4.117 | -4.524 | -4.876 | -6.257 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4800 | -0.3500 | -0.3800 | -0.3500 | -0.3600 | -0.4100 | -0.3900 | -0.4150 | -0.3950 | -0.3850 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/23 | 3/24/23 | 5/8/23 | 8/8/23 | 11/7/23 | 3/21/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/11/22 | 3/24/23 | 3/21/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.89
USD
Average target price
12.62
USD
Spread / Average Target
+336.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +147.01% | 59.48M | |
| +23.37% | 47.02B | |
| +48.83% | 41.86B | |
| -0.94% | 41.76B | |
| -5.86% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- MAIA Stock
- Financials MAIA Biotechnology, Inc.